読み込み中
NASDAQHealthcareBiotechnology
最新データ
$18.15
+$0.24 · +1.34%
Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions. The company is primarily engaged in tackling disorders like depression and anxiety, utilizing its unique Glyph technology. This exclusive platform is engineered to allow for oral administration of drugs, circumventing initial metabolic processing in the liver, and thereby reducing the risk of liver enzyme elevations, hepatotoxicity, and other potential adverse reactions. Every therapeutic agent in their pipeline incorporates this advanced platform, with all research and development efforts exclusively dedicated to neuropsychiatric applications. Founded in 2024 and situated in Boston, Massachusetts, the company connects with medical professionals and influential experts across the healthcare and neuropsychiatric sectors.
前日終値
$18.15
+$0.24 · +1.34%
日中の時刻はETです。市場データは遅延する場合があります。
Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions. The company is primarily engaged in tackling disorders like depression and anxiety, utilizing its unique Glyph technology. This exclusive platform is engineered to allow for oral administration of drugs, circumventing initial metabolic processing in the liver, and thereby reducing the risk of liver enzyme elevations, hepatotoxicity, and other potential adverse reactions. Every therapeutic agent in their pipeline incorporates this advanced platform, with all research and development efforts exclusively dedicated to neuropsychiatric applications. Founded in 2024 and situated in Boston, Massachusetts, the company connects with medical professionals and influential experts across the healthcare and neuropsychiatric sectors.
日中レンジ
現在 $18.15
52週レンジ
現在 $18.15
日中の時刻はETです。市場データは遅延する場合があります。
Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions. The company is primarily engaged in tackling disorders like depression and anxiety, utilizing its unique Glyph technology. This exclusive platform is engineered to allow for oral administration of drugs, circumventing initial metabolic processing in the liver, and thereby reducing the risk of liver enzyme elevations, hepatotoxicity, and other potential adverse reactions. Every therapeutic agent in their pipeline incorporates this advanced platform, with all research and development efforts exclusively dedicated to neuropsychiatric applications. Founded in 2024 and situated in Boston, Massachusetts, the company connects with medical professionals and influential experts across the healthcare and neuropsychiatric sectors.
日中レンジ
現在 $18.15
52週レンジ
現在 $18.15
| 指標（USD） | 2025年度 |
|---|---|
| 研究開発 | 6631.3万 USD |
| 販売・一般管理 | 2098.1万 USD |
| 営業費用 | 8729.4万 USD |
| 受取利息 | 1140.3万 USD |
| 減価償却費と償却費 | 140.5万 USD |
| 営業利益 | −8729.4万 USD |
| 純利益 | −7488.1万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$43.00
上昇余地（136.91%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI1009.65万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM646.75万0.01%787.4億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF396.79万0.00%954億 USD0.05%$235+0.80%
AdvisorShares Psychedelics ETFPSIL158.51万3.38%4685.29万 USD1.84%$21.765+3.69%
Schwab U.S. Small-Cap ETFSCHA139.02万0.01%218.24億 USD0.03%$32.79+0.40%
iShares Russell 2000 Growth ETFIWO138.35万0.01%139.17億 USD0.24%$356.78+0.94%
ALPS Medical Breakthroughs ETFSBIO123.4万0.64%1.91億 USD0.50%$55.04+2.03%
iShares Micro-Cap ETFIWC80.32万0.06%13.17億 USD0.60%$183+0.11%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFAdvisorShares Psychedelics ETFPSILSchwab U.S. Small-Cap ETFSCHAiShares Russell 2000 Growth ETFIWOALPS Medical Breakthroughs ETFSBIOiShares Micro-Cap ETFIWCAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
